This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
What's in the Cards for UnitedHealth (UNH) Earnings in Q3?
by Zacks Equity Research
UnitedHealth's (UNH) Q3 earnings are expected to be benefited from higher revenues and membership growth.
5 Insurance Stocks Poised to Beat Q3 Earnings Estimates
by Tanuka De
We have identified five insurers poised to outshine in the third quarter banking on solid fundamentals.
Will Lower Interest Rates Hurt Schwab (SCHW) in Q3 Earnings?
by Zacks Equity Research
Schwab's (SCHW) interest revenues in the third quarter are likely to have been adversely impacted by the recent decline in rates.
Why Earnings Beat is Less Likely for BlackRock (BLK) in Q3
by Zacks Equity Research
While steady iShares inflows are expected to have aided BlackRock's (BLK) assets under management in the third quarter of 2019, higher costs might have hurt results to some extent.
Primerica Stock Up 22% YTD: Will the Momentum Continue?
by Zacks Equity Research
Primerica's (PRI) operational excellence and growth initiatives help the stock continue the bull run.
Options Traders Expect Huge Moves in Cigna (CI) Stock
by Zacks Equity Research
Investors need to pay close attention to Cigna (CI) stock based on the movements in the options market lately.
Attractive Sales Growth Makes These 5 Stocks Worth Buying
by Swayta Shah
Sales growth is a key measure for any company, as it is important for earnings projections and strategic decision making.
UnitedHealth Expands Medicare Offerings in New Counties
by Zacks Equity Research
UnitedHealth (UNH) is offering Medicare Advantage plans in new counties to reach a greater population of retirees.
Cigna (CI) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Cigna (CI) closed at $150.74 in the latest trading session, marking a +1.43% move from the prior day.
Humana Penetrates Further in New Jersey Via PPO, HMO Plan
by Zacks Equity Research
Humana (HUM) expands its footprint in New Jersey to facilitate the locals with better healthcare solutions.
Can Cigna (CI) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cigna Offers 2020 Medicare Plans with Supplemental Benefits
by Sapna Bagaria
Cigna (CI) is expanding its Medicare Advantage plans across states and counties along with supplemental benefits
The Zacks Analyst Blog Highlights: UnitedHealth, Cigna, Anthem and Humana
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Cigna, Anthem and Humana
3 Health Insurance Stocks Poised to Beat on Earnings in Q3
by Sapna Bagaria
Growth in government and pharmacy benefit management businesses as well as share buybacks should enhance the third-quarter earnings of health insurers.
Are Investors Undervaluing Cigna (CI) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cigna (CI) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Cigna (CI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cigna Expands Health Care Exchange Offerings to New Markets
by Zacks Equity Research
Cigna (CI) expands the health care exchange plan to new regions beginning 2020 to enrich customer experience.
Here's How Cigna (CI) is Poised Amid Political Uncertainty
by Zacks Equity Research
Growth in health services, government business and international markets drive Cigna's (CI) stock.
Here's Why You Should Invest in Radian Group (RDN) Stock Now
by Zacks Equity Research
Radian Group (RDN) is poised to grow over the long term given its operational excellence and growth initiatives.
Why Is Cigna (CI) Down 8.1% Since Last Earnings Report?
by Zacks Equity Research
Cigna (CI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Zacks Analyst Blog Highlights: First Horizon National, Cigna, Ally Financial and Och-Ziff Capital Management
by Zacks Equity Research
The Zacks Analyst Blog Highlights: First Horizon National, Cigna, Ally Financial and Och-Ziff Capital Management
Here's Why Cigna (CI) is an Attractive Investment Option Now
by Zacks Equity Research
Cigna (CI) remains well poised for growth on the back of Express Scripts acquisition.
Magellan Healths Growth Measures Aid Investors' Confidence
by Zacks Equity Research
Magellan Health's (MGLN) initiatives to add new business and reduce cost of goods sold aid growth.
Are Investors Wrong in Selling These 4 Finance Stocks Now?
by Zacks Equity Research
While several global economic and geopolitical concerns have led to sell-off in the finance stocks recently, the industry's fundamental strength and growth initiatives keep it poised for growth.
Is Cigna (CI) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.